Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Immunogenicity of Anti-TNF Therapies in a Cohort of Patients with Inflammatory Bowel Disease from the Middle East: Frequency, Influencing Factors, and Contextual Drug Level Thresholds

  • By

  • Shaima Wasim Khan

  • Noorah Al Hosani

  • Thaer Khaleel Swaid

  • Mazin M Edan

  • Mohammed Nabil Quraishi

  • June 26, 2026

Share

Original Source(s)

Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds

  • by Shaima Wasim Khan, Noorah Al Hosani, Thaer Khaleel Swaid, Mazin M Edan, Mohammed Nabil Quraishi

  • June 26, 2026

Related Content

Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis

Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan

Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease